Kynexis
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $57M
Overview
A neuroscience company developing precision therapies for cognitive impairment in brain disorders.
NeurosciencePsychiatry
Technology Platform
A precision neuroscience platform focused on targeting D-amino acid oxidase (DAO) to modulate NMDA receptor function and improve cognitive deficits.
Funding History
1Total raised:$57M
Series A$57M
Opportunities
Addressing a massive unmet need in cognitive impairment with a precision approach that could demonstrate clear efficacy in a defined patient population.
Risk Factors
Clinical risk is high, as demonstrating robust cognitive improvement in CNS disorders has proven extremely difficult for many drug candidates.
Competitive Landscape
Operates in the challenging cognitive therapeutics space, competing with larger pharma and biotechs also targeting glutamatergic signaling (e.g., Cerevel, Karuna).